Business Wire

HUANGSHAN-TOURISM

Share
The Grand Huangshan Region Makes Its Debut at ITB Berlin 2024

Incorporated tourism contents from not only Mount Huangshan itself, but also with attractions in its neighborhood, the Grand Huangshan region made its debut at ITB Berlin 2024, the world’s leading travel trade show with over 5,500 exhibitors from 170 countries and regions, which concluded in Berlin on Thursday.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307230072/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Famous scenery such as pine trees, cloud seas, peculiarly-shaped stone peaks of Mount Huangshan in East China's Anhui province. (Photo: Business Wire)

Located in East China's Anhui province, Mount Huangshan, also known as the Yellow Mountain, is famous for its pine trees, cloud seas, peculiarly-shaped stone peaks, hot springs and winter snow scenery. With its natural and cultural values well interconnected, Huangshan was inscribed on the UNESCO World Cultural and Natural Heritage List in 1990.

This year marks the fifth consecutive participation of Huangshan Tourism Co., Ltd. (HSTD) in the ITB. Compared to the conventionally produced booths of previous years, HSTD innovatively designed its booth with the theme of the world-class leisure and wellness tourism destination, the Grand Huangshan region, this time.

They incorporated elements from tourist attractions, intangible cultural heritage skills, and traditional Huizhou cuisine of the four core cities in the Grand Huangshan region: Huangshan, Anqing, Chizhou, and Xuancheng. The booth featured a backdrop of traditional Chinese landscape paintings, adorned with simplified drawings of Huizhou-style architectural features, presenting a fresh image to exhibitors and visitors from around the world.

Meanwhile, a series of introduction material like visitor's guide and creative designed souvenirs have been distributed during the event. And the Grand Huangshan regional tourism resources, Huizhou cultural characteristics and high-quality international tourist routes were introduced at ITB as well, inviting international guests.

Many visitors expressed that they looked forward to having the opportunity to visit Huangshan and will introduce the beautiful scenery of Huangshan to more people.

According to HSTD, it’s already the second splendid appearance on the international stage for Huangshan, after the London Trafalgar Square Chinese New Year Celebration event early in February. It is also a significant step in implementing Huangshan City's global promotion plan for the urban brand "Creative Huangshan, Beauty in Huizhou."

In recent years, Huangshan Tourism has been dedicated to international exchange, cooperation, and brand promotion. It has actively participated in internationally influential cultural and tourism exchange events such as the New York Asian Cultural Festival, the United Nations "Journey Through Civilizations" photo exhibition, and the New York "Chinese Night."

Simultaneously, there has been a continuous increase in efforts to promote the brand worldwide, showcasing the tourism resources and cultural heritage of the beautiful Huangshan to overseas residents and tourists through multi-dimensional, comprehensive, and close-range approaches.

According to Huangshan, it will continue to spare no effort in showcasing the image of the Huangshan to international tourists in a fresh and compelling way and enhancing the visibility and influence of Grand Huangshan region as an international famous tourism destination.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307230072/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye